$SOBR

TransBiotec, Inc.

CIK:0001425627|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenues	$ 29,075	$ 104,228	$ 108,078	$ 190,845
Cost of goods and services	146,399	44,344	180,484	79,997
Gross profit (loss)	(117,324)	59,884	(72,406)	110,848
Operating expenses:
General and administrative	1,831,475	1,815,028	4,155,464	3,638,497
Stock-based compensation expense	5,701	115,252	12,944	254,930
Research and development	7,049	198,675	30,742	239,599
Asset impairment loss	1,105,052	0	1,105,052	0
Total operating expenses	2,949,277	2,128,955	5,304,202	4,133,026
Loss from operations	(3,066,601)	(2,069,071)	(5,376,608)	(4,022,178)
Other income (expense):
Other income, net	6,735	75,713	27,286	153,430
Interest expense	(1,818)	(2,127)	(5,284)	(5,792)
Total other income (expense), net	4,917	73,586	22,002	147,638
Loss before provision for income taxes	(3,061,684)	(1,995,485)	(5,354,606)	(3,874,540)
Provision for income taxes	0	0	0	0
Net loss	(3,061,684)	(1,995,485)	(5,354,606)	(3,874,540)
Net loss attributable to noncontrolling interest	4	5	8	9
Net loss attributable to SOBR Safe, Inc.	(3,061,680)	(1,995,480)	(5,354,598)	(3,874,531)
Deemed dividends related to Convertible Debt Warrants down round provision	0	0	0	(1,833)
Deemed dividends related to 2024 PIPE Warrants down round provision	0	0	0	(1,547)
Deemed Dividends related to 2024 PIPE Warrants round down provision	0	0	0	(47,373)
Net loss attributable to common stockholders	$ (3,061,680)	$ (1,995,480)	$ (5,354,598)	$ (3,925,284)
Basic and diluted loss per common share	$ (1.08)	$ (1.32)	$ (2.00)	$ (2.77)
Weighted average number of common shares outstanding	2,843,485	1,516,202	2,670,862	1,418,915

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating Activities:
Net loss	$ (5,354,606)	$ (3,874,540)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	144,889	192,732
Non-cash lease expense	54,706	49,298
Non-cash interest expense	1,145	0
Non-cash disposal of obsolete inventory	142,222	0
Non-cash asset impairment loss	1,105,052	0
Bad debt expense	22,331	0
Stock-based compensation expense	12,944	254,930
Changes in assets and liabilities:
Accounts receivable	1,586	(22,524)
Inventory	4,300	35,112
Prepaid expenses	193,803	115,082
Other assets	21,160	41,918
Accounts payable	(130,947)	63,738
Accrued expenses	(532,907)	(133,086)
Accrued interest payable	1,902	4,251
Deferred revenue	13,924	13,680
Operating lease liabilities	(61,110)	(53,794)
Net cash used in operating activities	(4,359,606)	(3,313,203)
Financing Activities:
Repayments of notes payable - non-related parties	(61,764)	(100,907)
Proceeds from exercise of stock warrants	91,068	3,680,411
Payment of transactional costs for exercise of warrants	0	(184,021)
Net cash provided by financing activities	29,304	3,395,483
Net Change In Cash	(4,330,302)	82,280
Cash At The Beginning Of The Period	4,759,370	8,384,042
Cash At The End Of The Period	429,068	8,466,322
Schedule Of Non-Cash Investing And Financing Activities:
True-up payment accrual related to 2024 PIPE Warrants	0	(1,640,000)
Deemed dividends related to Convertible Debt Warrants down round provision	0	(1,833)
Deemed dividends related to 2024 PIPE Warrants down round provision	0	(1,547)
Deemed dividends related to 2024 PIPE warrants round down provision	0	(47,373)
Supplemental Disclosure:
Cash paid for interest	2,232	1,541
Cash paid for income taxes	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash	$ 429,068	$ 4,759,370
Accounts receivable, net	11,990	35,907
Inventory	0	146,522
Prepaid expenses	73,963	267,766
Other current assets	211	21,371
Total current assets	515,232	5,230,936
Property and equipment, net	30,538	34,355
Intellectual technology, net	0	1,246,124
Operating lease right-of-use assets, net	27,674	82,380
Other assets	27,427	27,427
Total Assets	600,871	6,621,222
Current liabilities
Accounts payable	353,784	484,731
Accrued expenses	364,644	866,335
Accrued interest payable	117,948	114,901
Deferred revenue	20,524	6,600
Operating lease liabilities, current portion	30,883	91,993
Notes payable - related parties, net	11,810	11,810
Notes payable - non-related parties, net	26,683	119,663
Total current liabilities	926,276	1,696,033
Total Liabilities	926,276	1,696,033
Stockholders' Equity (Deficit)
Common stock, $0.00001 par value; 100,000,000 shares authorized, 2,876,579 and 1,886,255 shares issued and 2,876,562 and 1,886,238 shares outstanding at June 30, 2026 and December 31, 2025, respectively	29	19
Treasury stock, at cost; 17 shares as of June 30, 2026 and December 31, 2025	(38,015)	(38,015)
Additional paid-in capital	112,451,143	112,347,141
Accumulated deficit	(112,684,850)	(107,330,252)
Total SOBR Safe, Inc. stockholders' equity (deficit)	(271,693)	4,978,893
Noncontrolling interest	(53,712)	(53,704)
Total Stockholders' Equity (Deficit)	(325,405)	4,925,189
Total Liabilities and Stockholders' Equity	$ 600,871	$ 6,621,222